B
Bruce M. Ewenstein
Researcher at Baxter International
Publications - 74
Citations - 4114
Bruce M. Ewenstein is an academic researcher from Baxter International. The author has contributed to research in topics: Haemophilia & Population. The author has an hindex of 30, co-authored 71 publications receiving 3787 citations.
Papers
More filters
Journal ArticleDOI
Intramyocardial, Autologous CD34+ Cell Therapy for Refractory Angina
Douglas W. Losordo,Timothy D. Henry,Charles J. Davidson,Joon S. Lee,Marco A. Costa,Theodore A. Bass,Farrell O. Mendelsohn,F. David Fortuin,Carl J. Pepine,Jay H. Traverse,David L. Amrani,Bruce M. Ewenstein,Norbert Riedel,Kenneth Story,Kerry Barker,Thomas J. Povsic,Robert A. Harrington,Richard A. Schatz +17 more
TL;DR: Patients with refractory angina who received intramyocardial injections of autologous CD34+ cells (105 cells/kg) experienced significant improvements in angina frequency and exercise tolerance.
Journal ArticleDOI
Role of prothrombin complex concentrates in reversing warfarin anticoagulation: a review of the literature.
TL;DR: A review of the published literature over the last 30 years found that PCCs offer a rapid and specific method for replacing vitamin K‐dependent clotting factors and restoring normal hemostasis in the context of over‐coagulation.
Journal ArticleDOI
Break-through bleeding in relation to predicted factor VIII levels in patients receiving prophylactic treatment for severe hemophilia A
Peter William Collins,Victor Blanchette,Krista Fischer,Sven Björkman,Myungshin Oh,Sandor Fritsch,Phillip Schroth,Gerald Spotts,Jan Astermark,Bruce M. Ewenstein +9 more
TL;DR: It is demonstrated that increasing time with a FVIII below 1 IU dL−1 is associated with increased total bleeds and hemarthroses, and has important implications for the management of patients with severe hemophilia.
Journal ArticleDOI
Pegylated, full-length, recombinant factor VIII for prophylactic and on-demand treatment of severe hemophilia A
Barbara A. Konkle,Oleksandra Stasyshyn,Pratima Chowdary,David H. Bevan,Tim Mant,Midori Shima,Werner Engl,Jacqueline A. Dyck-Jones,Monika Fuerlinger,Lisa Patrone,Bruce M. Ewenstein,Brigitt E. Abbuehl +11 more
TL;DR: Evidence is provided that BAX 855 was safe and efficacious for on-demand treatment and prophylaxis administered twice weekly in patients with hemophilia A and for the treatment of bleeding episodes.
Journal ArticleDOI
Population pharmacokinetics of recombinant factor VIII : the relationships of pharmacokinetics to age and body weight
Sven Björkman,Myungshin Oh,Gerald Spotts,Phillip Schroth,Sandor Fritsch,Bruce M. Ewenstein,Kathleen M. Casey,Krista Fischer,Victor Blanchette,Peter William Collins +9 more
TL;DR: The relationships of the PK of factor VIII (FVIII) with age and body weight by a population PK model can be used as a basis for PK-based dose tailoring of FVIII in clinical practice, in all age groups, with minimal blood sampling.